Q-omics provides the consensus-scored NEGR1 profile across patient tissues and cancer cell-line models. NEGR1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NEGR1 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, NEGR1 protein abundance shows 26,877 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, BLCA, and GBM as cancer lineages where NEGR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NEGR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NEGR1 survival associations across molecular data types. NEGR1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NEGR1 RNA expression–survival associations across cancer types. High NEGR1 expression shows unfavorable associations in BLCA, UVM, OV and KIRP, but favorable associations in KIRC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NEGR1 RNA expression.
This table summarizes NEGR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NEGR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NEGR1 shows lower tumor expression in BLCA, KIRP, COAD, THCA, LUAD and KICH. The BLCA box plot shows higher NEGR1 RNA expression in normal versus tumor tissue (log2 FC = −3.960, t-test p < 0.001).
This table shows molecular features associated with NEGR1 in patient tissues and cancer cell lines. In patient samples, NEGR1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NEGR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and SOFT_TISSUE.
